Martin K Thomsen
Overview
Explore the profile of Martin K Thomsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1391
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bakiri L, Tichet M, Marques C, Thomsen M, Allen E, Allen E, et al.
Dis Model Mech
. 2025 Jan;
18(1).
PMID: 39745082
Genetically engineered mouse models (GEMMs) are instrumental for modelling local and systemic features of complex diseases, such as cancer. Non-invasive, longitudinal cell detection and monitoring in tumors, metastases and/or the...
2.
Bakiri L, Hasenfuss S, Guio-Carrion A, Thomsen M, Hasselblatt P, Wagner E
Proc Natl Acad Sci U S A
. 2024 Apr;
121(18):e2404188121.
PMID: 38657045
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death. HCC incidence is on the rise, while treatment options remain limited. Thus, a better understanding of the molecular pathways involved...
3.
Cai H, Zhang B, Ahrenfeldt J, Joseph J, Riedel M, Gao Z, et al.
Nat Commun
. 2024 Mar;
15(1):2088.
PMID: 38453924
Metastatic prostate cancer (PCa) poses a significant therapeutic challenge with high mortality rates. Utilizing CRISPR-Cas9 in vivo, we target five potential tumor suppressor genes (Pten, Trp53, Rb1, Stk11, and RnaseL)...
4.
5.
Joseph J, Blaavand M, Cai H, Vernejoul F, Knopper R, Lindhardt T, et al.
Cancer Lett
. 2023 Nov;
579:216480.
PMID: 37931834
Glioblastoma (GBM) is an aggressive brain tumor with a median survival of 15 months and has limited treatment options. Immunotherapy with checkpoint inhibitors has shown minimal efficacy in combating GBM,...
6.
Thomsen M, Busk M
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686488
Prostate cancer is a common cancer among men and typically progresses slowly for several decades before becoming aggressive and spreading to other organs, leaving few treatment options. While large animals...
7.
Haldrup J, Andersen S, Labial A, Wolff J, Frandsen F, Skov T, et al.
Nucleic Acids Res
. 2023 Sep;
51(18):10059-10074.
PMID: 37678882
Implementation of therapeutic in vivo gene editing using CRISPR/Cas relies on potent delivery of gene editing tools. Administration of ribonucleoprotein (RNP) complexes consisting of Cas protein and single guide RNA...
8.
Ren F, Narita R, Rashidi A, Fruhwurth S, Gao Z, Bak R, et al.
EMBO J
. 2023 Aug;
42(19):e113118.
PMID: 37646198
Neurotropic viruses, including herpes simplex virus (HSV) types 1 and 2, have the capacity to infect neurons and can cause severe diseases. This is associated with neuronal cell death, which...
9.
Thomsen M
Cancers (Basel)
. 2022 Oct;
14(20).
PMID: 36291798
Clustered regularly interspaced short palindromic repeats (CRISPR) are widely used in cancer research to edit specific genes and study their functions. This applies both to in vitro and in vivo...
10.
Cai H, Agersnap S, Sjogren A, Simonsen M, Blaavand M, Jensen U, et al.
Cancers (Basel)
. 2022 Sep;
14(18).
PMID: 36139541
Prostate cancer is the most common cancer in men in the Western world and the number is rising. Prostate cancer is notoriously heterogeneous, which makes it hard to generate and...